Understanding Genetic Testing in Leiomyosarcoma

This study is for people with leiomyosarcoma (a rare cancer of smooth muscle tissue) and their family members. Researchers want to understand your beliefs and feelings about how leiomyosarcoma might be passed down in families and about genetic testing. They are also looking at how patients and families react to receiving genetic test results, especially if a change in the TP53 gene (a gene linked to cancer risk) is found. This study aims to help doctors better incorporate genetic testing into care for leiomyosarcoma patients. About 300 people are expected to join.

Study design
This is an observational study, meaning researchers will gather information without giving any specific treatments. It plans to include about 300 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your beliefs about leiomyosarcoma heritability will be measured up to one day from joining the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06875700

Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients

Recruiting
Not specifiedAges 18+Observational
University of Utah
~300 participants
Updated 2025-06-13 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Beliefs about the heritability of Leiomyosarcoma
Measured over up to 1 day from study enrollment
Leiomyosarcoma
1 sites across 1 states
Utah1

Opens a ready-to-send draft in your own email app — review before sending.

  • Beliefs about the heritability of Leiomyosarcomaup to 1 day from study enrollment

    This outcome will report the count of participants who self-reported a strong belief in heritability. Participants who responded on a questionnaire that sarcoma is somewhat or highly heritable are considered to have a strong belief in heritability. This outcome measure will be assessed on Day 1 of the study.